|Last name||Michael Shepard|
Bioinformatics, Biotech, Cancer therapeutics, Clinical trials, Diagnostics, Drug Discovery, Immunology, Oncology, Personalised medicine, Therapeutics, biochemistry, cell biology, embryology, molecular biology, other, antibodies, gene therapy, other, antibodies, gene therapy
Quick: Invented Herceptin (Trastuzumab), received Harvard Medical School Warren Alpert Award and the Lasker Clinical Medicine Award. Most of my career has been biomarker-driven cancer therapy.
I have also worked in the area of rheumatoid arthritis and associated immunology.
My work is now focused on novel inhibitors of TNFR1 because the current generation of TNF Blockers have many side-effects, some of which are the result of the TNF Blockers’ inhibition of both TNFR1 and TNFR2. We have also devised a growth factor ‘trap’ that can prevent/inhibit the growth of cells in the inflammed rheumatoid joint, thus resulting in regression of RA in mouse models.
Easiest way to get a short introduction is to go here: https://en.wikipedia.org/wiki/H._Michael_Shepard
My company is Enosi Life Sciences, which is registered in the UK and in Delaware (www.enosi-life.com). This work is a collaboration with Prof. Sir Marc Feldmann at Oxford (https://en.wikipedia.org/wiki/Marc_Feldmann). We plan to begin a Reg A+ financing by the end of March, 2021. We have filed with the SEC and have had a couple rounds of questions. I am looking for a European Partner for a corresponding Reg A+ financing in Europe. I understand that these things are more restrictive in Europe, and so maybe only possible in the UK. Capital Cell is the most prominent group in this space.